Search Results - technology+classifications+%3e+healthcare+portfolios+%3e+immunology%2c+autoimmune+%26+inflammation

8 Results Sort By:
Peptide-Based Modulators of HMGBl Activity Protect Against Cell Damage and Inflammation
This technology assists with the inhibition of HMGB1 to decrease the body’s inflammatory response which occurs when the HMGB1 protein binds to DNA and TLR4. By decreasing HMGB1 binding to DNA, cell inflammation can be significantly reduced, thus preventing further cell damage. This technology can be used in a large spectrum of diseases, such as:...
Published: 5/5/2022   |   Inventor(s): Ruslan Rafikov, Olga Rafikova
Keywords(s):  
Category(s): Technology Classifications > Life Sciences, Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation
Novel Antibiotic Drug Combination Including an Anti-Inflammatory Metabolite
This technology involves a combination of a metabolite, 3-hydroxyanthanilic acid (3HAA) with a compound that alters cellular iron homeostasis (e.g. an iron chelator or an iron supplement) that produces synergistic antibiotic interaction. 3HAA sensitizes bacteria to changes in iron availability (both increasing iron media content through supplementation...
Published: 11/12/2021   |   Inventor(s): George Sutphin, Luis Espejo
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
Blood Biomarker for the Diagnosis and Treatment of Chronic Inflammation in the Brain in the Days and Weeks after Stroke
This invention comprises a method of identifying chronic inflammation in the day(s), weeks, or months after a stroke by measuring matrix metalloproteinase-12 (MMP-12) in a patient to determine whether therapeutic intervention is required to help immune cells process lipid debris after stroke to reduce secondary neurodegeneration. MMP-12 is a protein...
Published: 6/16/2021   |   Inventor(s): Kristian Doyle
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation, Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences, Technology Classifications > Life Sciences > Biomarkers, Technology Classifications > Life Sciences > Diagnostics, Technology Classifications > Research Tools > Protein
Oxytocin Analogues Bioavailable to the Brain for Non-Opioid Pain Relief and/or Addiction Treatment
Inventors at the University of Arizona have developed oxytocin analogues which have high potency, are designed to be more stable compared to the native oxytocin hormone (an endogenous peptide which inhibits pain and promotes social connection), have very high selectivity for oxytocin receptors, and are bioavailable for brain therapeutics. These druggable...
Published: 6/9/2021   |   Inventor(s): Lajos Szabo, Robin Polt, John Streicher, Michael Heien, Parthasaradhi Reddy Tanguturi
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation, Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences, Technology Classifications > Healthcare Portfolios > Neurology > Mental Health, Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
Protein Structure Analysis using One-Step Tyrosine Conjugation
This invention includes methods and systems for detecting, comparing, or evaluating proteins in an folded conformation, a particular bound state, or an aggregate state, and methods and systems for comparing amounts of labeling of a protein in a natural or control conformation and a denatured conformation. The methods of this invention may be used for...
Published: 12/2/2020   |   Inventor(s): Jacob Schwartz, John Jewett, Mahta Moinpour
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation, Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences, Technology Classifications > Healthcare Portfolios > Orphan Diseases, Technology Classifications > Life Sciences > Diagnostics, Technology Classifications > Research Tools > Screening assays, Technology Classifications > Research Tools > Protein
A Peptide Approach to Block eNOS Phosphorylation at T495
This invention is a peptide that blocks eNOS phosphorylation. These peptides are designed to target to block T495 phosporylation site of eNOS. When done, this would prevent the activation of eNOS that leads to superoxide production and overwhelming inflammation. The initial peptide has been shown to reduce NOS derived superoxide and cell barrier loss...
Published: 8/14/2020   |   Inventor(s): Stephen Black, Evgeny Zemskov, Qing Lu
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Heart and Vascular, Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation, Technology Classifications > Life Sciences > Biologics
An Individualized Method for Increasing Sleep Time via a Technology Platform
This technology is a software platform that focuses on sleep efficiency by incorporating individualized, self-correcting methods tailored to improve sleeping habits and increase sleeping time. The platform employs a comfortable, easily accessible wearable technology, and is intended to help adults suffering from lack of sleep to achieve better sleeping...
Published: 11/3/2016   |   Inventor(s): Michael Grandner, Michael Perlis
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation, Technology Classifications > Healthcare Portfolios > Sleep Disorders, Technology Classifications > Software & Information Technology > Health IT
Mixture of Estrogens Selective for Estrogen Receptor Beta for Treatment of Neurological or Psychiatric Disorders
This technology provides a mixture of estrogens that are selective for ER-β activation, offering a novel treatment for neurological and psychological disorders. Background: Mental disorders are the number one contributor to non-communicable diseases worldwide. Mental disorders such as schizophrenia, mood disorders, substance abuse and dementia...
Published: 2/17/2015   |   Inventor(s): Robert Handa, Jill Goldstein, Stuart Tobet
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation